DPP4 and diabetes mellitus: Is use of glucagon-like peptide-1 (GLP-1) receptor agonists among patients with diabetes and advanced-stage chronic kidney disease or end-stage kidney disease associated with better outcomes than use of dipeptidyl peptidase-4 (DPP-4) inhibitors?